Manufacturer
AbbVie Inc.
Contents
Beractant
Indication
Survanta is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. Survanta significantly reduces the incidence of RDS, mortality due to RDS and air leak complications.
Instruction
Intratracheal administration only. Survanta should be administered by or under the supervision of clinicians experienced in intubation, ventilator management, and general care of premature infants. The administration of Survanta is facilitated if one person administers the dose while another person positions and monitors the infant. Each dose of Survanta is 100 mg of phospholipids/kg birth weight (4 mL/kg).
Drug interaction
No Information provided
Malaysia
